Development · 15 Oct 2026
BIOCON, full dossier5 publishers have reported this development. Each act of reporting is below, cited.
Biocon has entered into a global settlement and licence agreement with Genentech, securing the earliest licensed launch dates for Pebrilzo, its biosimilar to the reference product Perjeta (pertuzumab).
Biocon has entered into a global settlement and license agreement with Genentech for breast cancer drug Pebrilzo, its biosimilar to the reference product Perjeta.
Biocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta.
Biocon Ltd has entered into a global settlement and license agreement with US based biotech major Genentech for its drug Pebrilzo, a biosimilar or copycat version of Genentech's breast cancer drug Perjeta (Pertuzumab).
16 Nov 2026 · 4 publishers
5 Nov 2026 · 2 publishers
4 Nov 2026 · 1 publisher
27 Oct 2026 · 1 publisher
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.